<DOC>
	<DOCNO>NCT02541877</DOCNO>
	<brief_summary>To observe clinical outcome different valve size strategy treat type-0 Bicuspid Aortic Stenosis ( BAS ) self-expandable transcatheter aortic valve implantation ( TAVI ) valve , compare standard size strategy normal Tricuspid Aortic Stenosis ( TAS ) .</brief_summary>
	<brief_title>Sizing-sTrategy Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve</brief_title>
	<detailed_description>BACKGROUND : From current clinical experience , investigator mostly choose small self-expandable transcatheter valve type-0 BAS TAS , combine `` balloon sizing '' strategy . But prospective randomized study show rationality clinical outcome different size strategy type-0 BAS self-expandable transcatheter valve . AIM : To observe clinical outcome different valve size strategy treat type-0 BAS self-expandable transcatheter aortic valve implantation ( TAVI ) valve , compare standard size strategy normal TAS . POPULATION : All patient severe degenerative aortic valve stenosis refer aortic valve intervention screen study eligibility . To included subject must 65 year old , anatomical technical eligible intervention , expect survive 1 year intervention , able provide write informed consent . Study exclusion criterion include isolate aortic valve regurgitation significant valve disease , unstable preoperative condition . DESIGN : The project multicenter randomize clinical trial . Patients type-0 BAS fulfil inclusion exclusion criterion randomize either Down size group Standard size group . Randomization 1:1 53 subject group . Meanwhile patient TAS fulfil inclusion exclusion criterion include Standard group study . Screening inclusion commence September 2015 . Inclusion expect last 3 year , subject follow 5 year .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Patients symptomatic severe aortic stenosis ( echocardiographic criterion : AV effective orifice area ( EOA ) &lt; 1 cm2 , mean AV gradient &gt; 40 mmHg , AV peak systolic velocity &gt; 4.0 m/s ; NYHAclass II great , angina pectoris , syncope ) 2 . Subject informed nature study , agree provision provide write informed consent . 3 . The subject agree comply specify followup evaluation return investigational site procedure perform . 4 . Patients technical anatomical eligible intervention 1 . A known hypersensitivity contraindication follow adequately premedicated : Aspirin Heparin ( HIT/HITTS ) bivalirudin Nitinol ( titanium nickel ) Ticlopidine clopidogrel Contrast medium 2 . Subject refuse blood transfusion . 3 . Other medical , social , psychological condition opinion Investigator precludes subject appropriate consent . 4 . Native aortic annulus size &lt; 20 mm &gt; 29 mm per baseline diagnostic imaging . 5 . Life expectancy less one year</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>